Seal Rock Therapeutics, a clinical-stage company focused on therapies for diseases with limited treatment options, has joined The Michael J. Fox Foundation’s LRRK2 Investigative Therapeutics Exchange (LITE) program, according to the company. The company said that this initiative supports the development of novel therapies targeting LRRK2 for Parkinson’s disease, incorporating Seal Rock’s brain-penetrant LRRK2/ASK1 signaling complex (LASC) inhibitors.
The company claims that its LASC inhibitors are first-in-class oral molecules that concurrently block LRRK2 and ASK1, which the company says enhances efficacy compared to targeting either protein alone and avoids the kidney and lung toxicity associated with many LRRK2 inhibitors.
The LITE program, the company said, fosters international collaboration among over 30 academic and clinical centres and more than a dozen companies, aiming to accelerate the advancement of LRRK2-targeted therapeutics through shared resources and open-science principles.
